Does carbon dioxide reduce the chance of kidney problems in minimally invasive (endovascular) artery treatments?
| ISRCTN | ISRCTN23564393 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN23564393 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Integrated Research Application System (IRAS) | 340062 |
| Protocol serial number | CPMS 55634, NIHR Central Commissioning Facility (CCF) Grant Code: NIHR206198 |
| Sponsor | University of Leicester |
| Funder | Research for Patient Benefit Programme |
- Submission date
- 12/11/2024
- Registration date
- 29/11/2024
- Last edited
- 03/12/2025
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
One in five people suffer from narrowings or blockages in their leg arteries. This is called peripheral arterial disease (PAD). It leads to poor leg circulation, which can cause leg gangrene or infection. Sometimes this may even lead to amputation. To prevent this from happening, the affected arteries have to be opened. This is usually done using X-rays and balloons to stretch the arteries open. These procedures are the most common artery surgeries in the NHS. To be able to do these procedures, doctors use a dye injected into the artery. This dye can affect kidney function. Instead of the usual dye that causes kidney problems, carbon dioxide can be used. Carbon dioxide does not affect the kidneys. No previous research, however, has tested whether using carbon dioxide does indeed protect the kidneys in these procedures. This study aims to perform a multicentre trial to assess whether using an automated CO2 injector reduces the impact of endovascular revascularisation on renal function in patients with PAD and chronic kidney disease by reducing the amount of iodinated contrast medium necessary to complete the revascularisation. The study will also assess the acceptability, feasibility and factors that may influence the implementation of this technology in the NHS from the perspective of patients and practitioners and record and report the overall costs of performing endovascular lower limb revascularisation using an automated CO2 injector versus the usual NHS standard of care.
Who can participate?
People with peripheral arterial disease who are having a procedure to open their arteries
What does the study involve?
What does the study involve, and what can participants expect?
The KID trial is exploring the use of two types of contrast dyes in a procedure called endovascular revascularisation. This procedure is commonly performed to treat blocked leg arteries, improving blood flow and preventing complications such as severe pain, tissue damage, or even amputation in patients with Peripheral Arterial Disease (PAD).
The study focuses on comparing:
• Iodine-based contrast: A liquid dye that is the standard option in the NHS. While effective, it may negatively affect kidney function, particularly in patients with reduced kidney health.
• Carbon dioxide (CO₂) contrast: A gas already used for patients with impaired kidney function. CO₂ is quickly absorbed by the body and does not harm the kidneys, but further research is required to confirm its effectiveness compared to iodine-based contrast.
Participants will undergo the standard endovascular revascularisation procedure. This involves inserting a small, flexible tube (called a sheath) into a blood vessel, typically near the groin, to access the blocked arteries. During the procedure, either iodine-based contrast or CO₂ contrast will be used to visualise the arteries. If CO₂ does not provide clear enough images during the procedure, the team will switch to iodine-based contrast to ensure the procedure is completed effectively.
Participants will be randomly assigned to receive either iodine-based or CO₂ contrast as part of the study. Following the procedure, recovery will be closely monitored to evaluate the effectiveness of the contrast used, as well as to identify any potential side effects or complications.
The trial’s goal is to determine which contrast is safer and more effective for patients with PAD and Chronic Kidney Disease (CKD). Additionally, the study will assess which option is more cost-effective for the NHS.
By participating in this research, individuals contribute to valuable insights that could help improve treatment options for patients with PAD and CKD, potentially influencing future care standards in the NHS and beyond.
What are the possible benefits and risks of participating?
There are no guaranteed direct benefits to taking part in the trial. Participant’s condition may remain the same, improve, or worsen. However, given that the research team will be in regular contact with the participant to monitor their health following the procedure, they may receive more frequent follow-up care compared to someone not participating in the trial.
All participants taking part in this trial will be helping to make a significant contribution to the research. The results of this trial may lead to better treatment for other patients with coexisting PAD and CKD in the future.
All medical procedures carry some risks. Below are the relevant risks and side effects associated with both the procedure and the contrast mediums used in this trial:
• Iodine-based contrast risks: Iodine contrast can sometimes impact kidney function, which may be more challenging for those with CKD. It can also occasionally cause allergic reactions, though these are rare.
• CO₂ contrast risks: The CO₂ gas injection method may cause mild discomfort or a "tingling" sensation at the injection site. There is also a small risk that the CO₂ injection could delay the procedure by a few minutes. However, because this trial uses an automated injector, any discomfort is expected to be considerably less than the usual injection of CO2 by hand. In rare cases, CO₂ injections may not provide a clear enough image, and the surgeon may switch to iodine contrast during the procedure.
The CO₂ gas used is safely absorbed by the body before it reaches vital areas, like the heart or brain, minimising the risk of complications. Although side effects are rare, your doctor and medical team will monitor you closely throughout the procedure and recovery.
Where is the study run from?
The KID trial is being run in the UK, across at least six NHS hospitals that provide specialist care for Peripheral Arterial Disease (PAD). These hospitals are equipped with an automatic injector system, which is a key component of the study and will be recruiting participants to take part in the trial.
When is the study starting and how long is it expected to run for?
March 2024 to August 2026 - The study grant started on 01/03/2024, the study duration is 30 months, in which recruitment takes place for 12 months, follow-up for 3 months and another 6 months for data lock and analysis.
Who is funding the study?
National Institute for Health and Care Research (NIHR) Research for Patient Benefit (RfPB) programme
Who is the main contact?
Dania Tapia-Aguirre, kidtrial@leicester.ac.uk
Contact information
Principal investigator
Professor Of Vascular Surgery
Department of Cardiovascular Sciences
BHF Cardiovascular Research Facility
University of Leicester
Glenfield Hospital
Groby Road
Leicester
LE3 9QP
United Kingdom
| Phone | +44 (0)753 141 8104 |
|---|---|
| as875@leicester.ac.uk |
Public, Scientific
Leicester Clinical Trials Unit
College of Life Sciences
University of Leicester
University Road
Leicester
LE1 7RH
United Kingdom
| Phone | +44 (0)116 373 6376 |
|---|---|
| KIDTrial@leicester.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | Preventing kidney injury using carbon dioxide as contrast medium in patients with peripheral arterial disease (PAD) and chronic kidney disease (CKD) having arterial intervention (the KID trial) |
| Study acronym | KID |
| Study objectives | Using carbon dioxide as a contrast medium via an automated injector will reduce the likelihood of short and medium-term decline in renal function in patients with peripheral arterial disease and chronic kidney disease, who are undergoing endovascular revascularisation. |
| Ethics approval(s) |
Approved 05/11/2024, Wales REC 7 (-, -, -, United Kingdom; -; Wales.REC7@wales.nhs.uk), ref: 24/WA/0332 |
| Health condition(s) or problem(s) studied | Peripheral arterial disease and chronic kidney disease |
| Intervention | Eligible patients identified by their doctors, radiologists, or any other member of their care team/healthcare professional will be given the patient information sheet prior to their procedure to review and ask any questions. If they are happy to continue, they will be consented to the trial, undergo baseline assessments, and then be randomised to either standard of care iodine contrast or carbon dioxide contrast. Baseline assessments in this trial will include collecting demographic data, height and weight, medical history and any concomitant medications; the serum creatinine (eGFR) value taken as part of the standard of care will be recorded, and the participant will be asked to complete the QoL questionnaires (EQ-5D-5L and SF-36), health care resource use questionnaire, and Theoretical Framework of Acceptability questionnaire. On the day of the index procedure, fluid administration and AKI prevention-related care will be recorded pre-op throughout the procedure and after. During the index operation, the participants will be asked about their pain score, procedural data and concomitant medications will also be documented. From post-procedure to discharge, an eGFR (standard of care) value will be recorded, as well as safety reporting, concomitant medications, and other procedure-related data collected. Participants will then have 2 follow-up appointments post-discharge, at 30 and 90 days post-procedure, which will be conducted either in person or over the phone where their eGFR values will be collected along with any concomitant meds, safety reviews, and fluid/AKI-related info will be recorded. At the 90-day follow-up, participants will be asked to complete the QoL questionnaires again, as well as a health care resource use questionnaire. For participants that agree to the optional interviews, the research team at the site and researchers at St George's (who are conducting the interviews) will organise the interview with the participant for roughly 3-4 weeks post-procedure to allow participants to recover from their procedure, but ensure they are still able to recall events from during their admission. There will also be three qualitative aspects for the practitioners involved in delivering the intervention, led by researchers at City St George's, University of London: a post-procedure questionnaire offered to all lead practitioners, to be completed within 3 days of the procedure; a cross-sectional practitioner questionnaire offered to all practitioners involved in delivering the intervention, with data collection beginning roughly halfway through trial recruitment and ongoing until the sample size is achieved; and optional practitioner interviews, which will take place during participant procedures and will begin at sites once the Cross-Sectional Questionnaire is nearing completion. |
| Intervention type | Other |
| Primary outcome measure(s) |
Log serum creatinine measured from the blood sample taken at 2, 30 and 90 days (part of the standard of care) after endovascular revascularisation |
| Key secondary outcome measure(s) |
Key secondary outcome measure: |
| Completion date | 31/08/2026 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 99 Years |
| Sex | All |
| Target sample size at registration | 174 |
| Key inclusion criteria | Current inclusion criteria as of 03/12/2025: 1. Age >18 years 2. Scheduled to undergo any revascularisation with an endovascular component 3. Estimated glomerular filtration rate <60 ml/kg/1.73m2 or established chronic kidney disease (two separate eGFR readings <60 ml/min/1.73m² in the last 3 months)* 4. Signed informed consent Previous inclusion criteria: 1. Age >18 years 2. Undergoing any revascularisation with an endovascular component 3. Estimated glomerular filtration rate <60 ml/min/1.73m2 4. Signed informed consent |
| Key exclusion criteria | 1. Known allergy to iodinated contrast media 2. Individuals already on long-term dialysis at the time of screening 3. An inability to understand the languages in which the trial materials are provided. |
| Date of first enrolment | 31/12/2024 |
| Date of final enrolment | 31/12/2025 |
Locations
Countries of recruitment
- United Kingdom
Study participating centres
Leicester
LE1 5WW
England
Tooting
London
SW17 0QT
England
London
SE1 7EH
England
Stoke-On-Trent
ST4 6QG
England
Oxford Road
Manchester
M13 9WL
England
Hull
HU3 2JZ
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | 28/05/2025 | 03/12/2025 | Yes | No |
Editorial Notes
03/12/2025: The following changes were made to the study record:
1. The inclusion criteria and contact details were updated.
2. Publication reference added.
12/11/2024: Study's existence confirmed by the National Institute for Health and Care Research (NIHR) (UK).
